ReviewCurrent atherosclerosis reports2013
Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.
Review in Current atherosclerosis reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis.Cardiorenal medicine · 2018 · on this mapPooled it
- Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.HIV medicine · 2014Trial
- Statin Use in Patients With Chronic Liver Disease and Cirrhosis: Current Evidence and Future Directions.Gastroenterology research · 2022Review
- Metronidazole enhances steatosis-related early-stage hepatocarcinogenesis in high fat diet-fed rats through DNA double-strand breaks and modulation of autophagy.Environmental science and pollution research international · 2022Article
- Radix Polygoni Multiflori and Its Main Component Emodin Attenuate Non-Alcoholic Fatty Liver Disease in Zebrafish by Regulation of AMPK Signaling Pathway.Drug design, development and therapy · 2020Article
- Effect of Soothing Gan (Liver) and Invigorating Pi (Spleen) Recipes on TLR4-p38 MAPK Pathway in Kupffer Cells of Non-alcoholic Steatohepatitis Rats.Chinese journal of integrative medicine · 2019Article
- Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.Current gastroenterology reports · 2017Review
- SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy.Scientific reports · 2016Article
- Low simvastatin concentrations reduce oleic acid-induced steatosis in HepGExperimental and therapeutic medicine · 2016Article
- Non-alcoholic fatty liver disease in 2015.World journal of hepatology · 2015Review
- Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.World journal of gastroenterology · 2014Review
- Perilipin-5 is regulated by statins and controls triglyceride contents in the hepatocyte.Journal of hepatology · 2014Article
- Hepatic steatosis and steatohepatitis: Are they really two distinct entities?Current hepatology reports · 2014Article
- Lessons from mouse models of high-fat diet-induced NAFLD.International journal of molecular sciences · 2013Review
- Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that refers to the presence of hepatic steatosis without significant intake of alcohol. NAFLD is an asymptomatic disease that can progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. The most common cause of mortality in patients with NAFLD or NASH is cardiovascular disease (CVD). Currently, the treatment of NAFLD focuses on gradual weight loss and life style modifications. However, multifactorial treatment of NAFLD or NASH risk factors may be needed to reduce the likelihood of these patients developing CVD. This review discusses the mechanisms that link hyperlipidemia and NAFLD. In addition, the review focuses on the safety and efficacy of statins in patients with NAFLD or NASH, and their effect on the extent of hepatic steatosis and fibrosis based on human studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.